Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Review article: Biomedical intelligence

Vol. 153 No. 2 (2023)

Bleeding on oral anticoagulants: overview of reversal strategies

  • Mauro Foletti
  • Thomas Schmutz
  • Yvan Fleury
  • Jean-Luc Magnin
  • Christophe Le Terrier
  • Youcef Guechi
DOI
https://doi.org/10.57187/smw.2023.40036
Cite this as:
Swiss Med Wkly. 2023;153:40036
Published
20.02.2023

Summary

Oral anticoagulants (antivitamin K, direct oral anticoagulants) are routinely prescribed for the prevention or treatment of thromboembolic events, and many patients are now on long-term anticoagulant therapy. However, this complicates the management of urgent surgical conditions or major bleeding. Various strategies have been developed to reverse the anticoagulant effect and this narrative review provides an overview of the wide range of therapies currently available.

References

  1. Groupe de travail RivaMoS Suisse. Questions et réponses sur l’utilisation du rivaroxaban (Xarelto) dans la pratique. Rev Med Suisse. 2013;9:1375–85.
  2. Chai-Adisaksopha C, Crowther M, Isayama T, Lim W. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood. 2014 Oct;124(15):2450–8. https://doi.org/10.1182/blood-2014-07-590323 DOI: https://doi.org/10.1182/blood-2014-07-590323
  3. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005 Apr;3(4):692–4. https://doi.org/10.1111/j.1538-7836.2005.01204.x DOI: https://doi.org/10.1111/j.1538-7836.2005.01204.x
  4. Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW, et al. 2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2017 Dec;70(24):3042–67. https://doi.org/10.1016/j.jacc.2017.09.1085 DOI: https://doi.org/10.1016/j.jacc.2017.09.1085
  5. Spahn DR, Bouillon B, Cerny V, Duranteau J, Filipescu D, Hunt BJ, et al. The European guideline on management of major bleeding and coagulopathy following trauma: Fifth edition. Crit Care. 2019;23:98. DOI: https://doi.org/10.1186/s13054-019-2347-3
  6. Kluger Y, Ben-Ishay O, Sartelli M, Ansaloni L, Abbas AE, Agresta F, et al. World society of emergency surgery study group initiative on Timing of Acute Care Surgery classification (TACS). World J Emerg Surg. 2013 May;8(1):17. https://doi.org/10.1186/1749-7922-8-17 DOI: https://doi.org/10.1186/1749-7922-8-17
  7. Haute Autorité de Santé. Prise en charge des surdosages en antivitamines K, des situations à risque hémorragique et des accidents hémorragiques chez les patients traités par antivitamines K en ville et en milieu hospitalier—avril 2008 [French.]. J Mal Vasc. 2008 Dec;33(4-5):202–13. https://doi.org/10.1016/j.jmv.2008.09.002 DOI: https://doi.org/10.1016/j.jmv.2008.09.002
  8. Huda SA, Kahlown S, Jilani MH, Chaudhuri D. Management of life-threatening bleeding in patients with mechanical heart valves. Cureus. 2021 Jun;13(6):e15619. https://doi.org/10.7759/cureus.15619 DOI: https://doi.org/10.7759/cureus.15619
  9. Pollack CV Jr. Coagulation assessment with the new generation of oral anticoagulants. Emerg Med J. 2016 Jun;33(6):423–30. https://doi.org/10.1136/emermed-2015-204891 DOI: https://doi.org/10.1136/emermed-2015-204891
  10. Sauter TC, Eberle B, Wuillemin WA, Thiele T, Angelillo-Scherrer A, Exadaktylos AK, et al. How I manage patients with anticoagulation-associated bleeding or urgent surgery. Swiss Med Wkly. 2018 Mar;148:w14598. DOI: https://doi.org/10.4414/smw.2018.14598
  11. Cuker A, Siegal DM, Crowther MA, et al. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol. 2014;64:1128-39 DOI: https://doi.org/10.1016/j.jacc.2014.05.065
  12. Samuelson BT, Cuker A, Siegal DM, Crowther M, Garcia DA. Laboratory assessment of the anticoagulant activity of direct oral anticoagulants. Chest. 2017 Jan;151(1):127–38. https://doi.org/10.1016/j.chest.2016.08.1462 DOI: https://doi.org/10.1016/j.chest.2016.08.1462
  13. DeAngelo J, Jarrell D, Cosgrove R, Camamo J, Edwards C, Patanwala AE. Comparison of 3-factor versus 4-factor prothrombin complex concentrate with regard to warfarin reversal, blood product use, and costs. Am J Ther. 2018;25(3):e326–32. https://doi.org/10.1097/MJT.0000000000000643 DOI: https://doi.org/10.1097/MJT.0000000000000643
  14. Levy JH, Ageno W, Chan NC, Crowther M, Verhamme P, Weitz JI; Subcommittee on Control of Anticoagulation. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost. 2016 Mar;14(3):623–7. https://doi.org/10.1111/jth.13227 DOI: https://doi.org/10.1111/jth.13227
  15. Jayaraman S, DeAntonio JH, Leichtle SW, Han J, Liebrecht L, Contaifer D, et al. Detecting direct oral anticoagulants in trauma patients using liquid chromatography-mass spectrometry: A novel approach to medication reconciliation. J Trauma Acute Care Surg. 2020 Apr;88(4):508–14. https://doi.org/10.1097/TA.0000000000002527 DOI: https://doi.org/10.1097/TA.0000000000002527
  16. Hickey M, Gatien M, Taljaard M, Aujnarain A, Giulivi A, Perry JJ. Outcomes of urgent warfarin reversal with frozen plasma versus prothrombin complex concentrate in the emergency department. Circulation. 2013 Jul;128(4):360–4. https://doi.org/10.1161/CIRCULATIONAHA.113.001875 DOI: https://doi.org/10.1161/CIRCULATIONAHA.113.001875
  17. Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, et al. Idarucizumab for dabigatran reversal — full cohort analysis. N Engl J Med. 2017 Aug;377(5):431–41. https://doi.org/10.1056/NEJMoa1707278 DOI: https://doi.org/10.1056/NEJMoa1707278
  18. Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH, et al.; ANNEXA-4 Investigators. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med. 2019 Apr;380(14):1326–35. https://doi.org/10.1056/NEJMoa1814051 DOI: https://doi.org/10.1056/NEJMoa1814051
  19. Moia M, Squizzato A. Reversal agents for oral anticoagulant-associated major or life-threatening bleeding. Intern Emerg Med. 2019 Nov;14(8):1233–9. https://doi.org/10.1007/s11739-019-02177-2 DOI: https://doi.org/10.1007/s11739-019-02177-2
  20. Simon EM, Streitz MJ, Sessions DJ, Kaide CG. Anticoagulation Reversal. Emerg Med Clin North Am. 2018 Aug;36(3):585–601. https://doi.org/10.1016/j.emc.2018.04.014 DOI: https://doi.org/10.1016/j.emc.2018.04.014
  21. Sarode R, Milling TJ Jr, Refaai MA, Mangione A, Schneider A, Durn BL, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013 Sep;128(11):1234–43. https://doi.org/10.1161/CIRCULATIONAHA.113.002283 DOI: https://doi.org/10.1161/CIRCULATIONAHA.113.002283
  22. Goldstein JN, Refaai MA, Milling TJ Jr, Lewis B, Goldberg-Alberts R, Hug BA, et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet. 2015 May;385(9982):2077–87. https://doi.org/10.1016/S0140-6736(14)61685-8 DOI: https://doi.org/10.1016/S0140-6736(14)61685-8
  23. Cuker A, Burnett A, Triller D, Crowther M, Ansell J, Van Cott EM, et al. Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum. Am J Hematol. 2019 Jun;94(6):697–709. https://doi.org/10.1002/ajh.25475 DOI: https://doi.org/10.1002/ajh.25475
  24. Swissmedic. OndexxyaTM, poudre pour solution pour perfusion (andexanet alfa). [Internet]. [cited 2021 Oct 1]. Available from: https://www.swissmedic.ch/swissmedic/fr/home/humanarzneimittel/authorisations/new-medicines/ondexxyatm-pulver-andexanet-alfa.html, accessed 23 May 2022).
  25. Volpe M, Jenny E, Guillermin A, Bloch J. Réversibilité des anticoagulants oraux directs : quid des nouveaux traitements disponibles? [Reversal of direct oral anticoagulants: what about new treatments available?]. Rev Med Suisse. 2022 Sep;18(794):1638–43. https://doi.org/10.53738/REVMED.2022.18.794.1638 DOI: https://doi.org/10.53738/REVMED.2022.18.794.1638
  26. Getta B, Muller N, Motum P, Hsu D, Zebeljan D, Rosenfeld D. Intermittent haemodialysis and continuous veno-venous dialysis are effective in mitigating major bleeding due to dabigatran. Br J Haematol. 2015 May;169(4):603–4. https://doi.org/10.1111/bjh.13236 DOI: https://doi.org/10.1111/bjh.13236

Most read articles by the same author(s)